Takeda Ventures

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Oshi Health is a virtual gastroenterology clinic specializing in diagnosing, treating, and remotely monitoring digestive conditions. Patients work with an integrated team of specialists to determine the root causes of symptoms and develop personalized care plans combining medication, dietary interventions, and gut-brain behavioral therapy.

PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives.

Ascentage Pharma is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers, hepatitis B virus (HBV), and age-related diseases. Its pipeline comprises seven drug candidates targeting protein-protein interactions and tyrosine kinases.

Maia Oncology operates a virtual cancer care coordination platform, serving as a comprehensive primary care clinic for cancer patients and survivors. The platform tracks patient outcomes, including hospitalizations, ER visits, and new comorbidities, enabling patients to navigate cancer-related toxicities and long-term complications.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Larkspur Biosciences specializes in developing precision immunotherapies for specific patient groups with molecularly defined cancers. Its focus is on targeting the interaction between tumors and the immune system to stimulate robust, long-lasting responses.

Oshi Health is a virtual gastroenterology clinic specializing in diagnosing, treating, and remotely monitoring digestive conditions. Patients work with an integrated team of specialists to determine the root causes of symptoms and develop personalized care plans combining medication, dietary interventions, and gut-brain behavioral therapy.

The American Red Cross (ARC), established in 1881 by Clara Barton, is a humanitarian organization dedicated to providing emergency assistance, disaster relief, and education across the United States. As the U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies, it plays a crucial role in disaster response and public safety. The ARC is the largest supplier of blood products in the country, collecting and processing around 40 percent of the nation's blood supply for distribution to approximately 2,600 hospitals and transfusion centers. The organization ensures the safety of the blood supply through rigorous testing and research, having been a pioneer in developing testing methods for various infectious diseases. Additionally, the ARC operates a nationwide hemovigilance program that monitors donor and patient reactions to improve blood product quality. Headquartered in Washington, D.C., the American Red Cross also collaborates with key committees and regulatory bodies, such as the U.S. Food and Drug Administration, to enhance safety standards in blood services.

Nimbus Lakshmi operates as a wholly-owned subsidiary of Nimbus Therapeutics and offers tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858, an orally administered, selective allosteric inhibitor of TYK2, is currently undergoing assessment for its potential in treating various autoimmune diseases, following promising Phase 2b outcomes in psoriasis.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

Oshi Health is a virtual gastroenterology clinic specializing in diagnosing, treating, and remotely monitoring digestive conditions. Patients work with an integrated team of specialists to determine the root causes of symptoms and develop personalized care plans combining medication, dietary interventions, and gut-brain behavioral therapy.

Turnstone Biologics is a clinical-stage biotechnology company focused on developing viral immunotherapies to improve cancer survival. Its lead candidate, RIVAL-01, combines three immunomodulators to stimulate immune activity and reprogram the tumor microenvironment.

Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Maverick Therapeutics, Inc. is a biotechnology company based in Brisbane, California, that specializes in developing T-cell engagement therapeutics aimed at treating solid tumor cancers. Founded in 2016, the company focuses on creating innovative immunotherapies that enhance safety and efficacy for patients. Its proprietary platform, COBRA™, is recognized as a leading bispecific T-cell engaging technology, engineered to target solid tumors with high specificity and potency. This novel platform addresses toxicity challenges associated with cancer treatments by remaining inactive upon administration and becoming fully active within the tumor microenvironment, thereby optimizing T-cell redirection therapy. Through its advancements, Maverick Therapeutics aims to improve patient outcomes and facilitate more effective cancer care.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Oshi Health is a virtual gastroenterology clinic specializing in diagnosing, treating, and remotely monitoring digestive conditions. Patients work with an integrated team of specialists to determine the root causes of symptoms and develop personalized care plans combining medication, dietary interventions, and gut-brain behavioral therapy.

Palleon Pharmaceuticals is a biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer. Its platform integrates insights from glycoscience and human immunology, enabling it to create novel therapies targeting multiple immune cell types.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Turnstone Biologics is a clinical-stage biotechnology company focused on developing viral immunotherapies to improve cancer survival. Its lead candidate, RIVAL-01, combines three immunomodulators to stimulate immune activity and reprogram the tumor microenvironment.

Oshi Health is a virtual gastroenterology clinic specializing in diagnosing, treating, and remotely monitoring digestive conditions. Patients work with an integrated team of specialists to determine the root causes of symptoms and develop personalized care plans combining medication, dietary interventions, and gut-brain behavioral therapy.

ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR, targeting neurodegenerative and neuroinflammatory diseases. The company utilizes unique computational methods to develop a series of novel and selective molecules, which are validated through clinically relevant assays. This approach aims to address issues such as memory consolidation impairment and enhance long-term memory in patients. In 2019, ProteKt Therapeutics graduated from the FutuRx accelerator and subsequently raised $4 million in a pre-A funding round to support its innovative research and development efforts.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Bsense Bio Therapeutics develops small-molecule therapeutics for sensory hyperexcitability-related disorders. It pursues a novel approach that targets multiple hyperexcitability mechanisms with a single compound, focusing on two cation channels: a ligand-gated cation channel and a voltage-gated potassium channel, to improve efficacy and safety.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

ARTham Therapeutics Inc is a biopharmaceutical company based in Naka-Ku, Japan, founded in 2018. The company focuses on delivering innovative biological medicines aimed at treating debilitating diseases. Its portfolio includes programs such as art-648, art-ep, art-pde, and art-001, which are designed to address specific medical needs in areas including inflammatory skin diseases, vascular malformations, and immuno-oncology endometriosis. Operating under a virtual research and development model, ARTham Therapeutics collaborates with academic and business partners to drive innovation and create disease-modifying therapies that enhance patient health and quality of life.

Reborna Biosciences specializes in researching and developing treatments for genetic diseases, focusing on areas with unmet medical needs. The company's core technology enables low-molecular compounds to target ribonucleic acid (RNA), leading to the creation of new disease-modifying drugs for patients suffering from rare genetic diseases such as spinal muscular atrophy.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Shire is a global biopharmaceutical company focused on developing and marketing therapies for rare diseases. It maintains a broad portfolio across hematology, immunology, neuroscience, ophthalmology, internal medicine and endocrine disorders, and hereditary angioedema. The company operates a worldwide sales and marketing network with direct marketing in the United States, Canada, the United Kingdom, Ireland, France, Germany, Italy and Spain. It emphasizes patient-focused care and aims to deliver innovative therapies to patients with rare diseases worldwide.

Fimecs is a biotechnology company that specializes in drug discovery focused on protein degradation technology. The firm aims to develop first-in-class therapeutics targeting the degradation of proteins associated with cancers and other challenging diseases. Utilizing a proprietary platform based on ubiquitin E3 ligase binders, Fimecs designs small molecules that can induce the degradation of specific proteins, many of which are considered undruggable. This innovative approach targets proteins linked to various diseases, expanding the potential for effective treatment options beyond the traditionally druggable targets identified in small molecule drug discovery. Through its emphasis on targeted protein degradation, Fimecs is positioned to contribute significantly to the advancement of anti-cancer therapies and the treatment of other hard-to-treat conditions.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Chordia Therapeutics Inc. is a clinical-stage biotechnology company based in Fujisawa, Japan, founded in 2017. The company specializes in the research and development of innovative oncology drugs, focusing on delivering first-in-class therapies for cancers that currently have high unmet medical needs. Chordia Therapeutics is committed to advancing new therapeutic options to patients as swiftly as possible, aiming to address significant gaps in cancer treatment.

Outpost Medicine is a biotechnology company founded in 2016 and based in the United States, focusing on the development of novel therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to creating innovative treatments for conditions such as overactive bladder and irritable bowel syndrome. Its lead clinical-stage product candidate, OP-233, targets stress urinary incontinence, a condition characterized by involuntary urine loss during physical activities that exert pressure on weakened pelvic floor muscles or urethral sphincters. Through its research and development efforts, Outpost Medicine aims to address significant unmet medical needs in these areas.

Palleon Pharmaceuticals is a biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer. Its platform integrates insights from glycoscience and human immunology, enabling it to create novel therapies targeting multiple immune cell types.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Scohia Pharma is a Fujisawa, Japan-based biopharmaceutical company focused on researching, designing, and developing therapies for metabolic, cardiovascular, and renal diseases. Its work targets lifestyle-related conditions such as obesity, diabetes, dyslipidemia, and hypertension, with an emphasis on delivering treatments that improve patient outcomes through research and development across metabolic and renal disorders.

Ariad Pharmaceuticals, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of innovative cancer therapies. The company’s flagship product, Iclusig (ponatinib), is a tyrosine kinase inhibitor approved for the treatment of adult patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in multiple regions, including the United States and Europe. Additionally, Ariad is developing Brigatinib, an investigational treatment targeting anaplastic lymphoma kinase for non-small cell lung cancer, as well as AP32788, aimed at treating non-small cell lung cancer and other solid tumors. The company markets Iclusig through specialty pharmacies in the U.S. Established in 1991, Ariad Pharmaceuticals operates as a subsidiary of Takeda Pharmaceuticals U.S.A., Inc., and remains committed to advancing therapies that transform the lives of cancer patients.

Maverick Therapeutics, Inc. is a biotechnology company based in Brisbane, California, that specializes in developing T-cell engagement therapeutics aimed at treating solid tumor cancers. Founded in 2016, the company focuses on creating innovative immunotherapies that enhance safety and efficacy for patients. Its proprietary platform, COBRA™, is recognized as a leading bispecific T-cell engaging technology, engineered to target solid tumors with high specificity and potency. This novel platform addresses toxicity challenges associated with cancer treatments by remaining inactive upon administration and becoming fully active within the tumor microenvironment, thereby optimizing T-cell redirection therapy. Through its advancements, Maverick Therapeutics aims to improve patient outcomes and facilitate more effective cancer care.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Bioniz Therapeutics, Inc. is a biopharmaceutical company based in Irvine, California, established in 2009. It specializes in discovering and developing innovative peptide therapeutics aimed at treating immune diseases and cancer. The company's pipeline includes BNZ-1, a selective inhibitor targeting interleukin cytokines IL2, IL9, and IL15, which are significant contributors to conditions such as HTLV-1 Associated Myelopathy and T-cell leukemias. Additionally, Bioniz is developing IL-15 and IL-21 inhibitors, as well as BNZ-3, an early-stage asset focused on inhibiting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics is committed to advancing its lead technologies through proof of concept and preclinical studies, with the goal of partnering for clinical trials and eventual commercialization.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Outpost Medicine is a biotechnology company founded in 2016 and based in the United States, focusing on the development of novel therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to creating innovative treatments for conditions such as overactive bladder and irritable bowel syndrome. Its lead clinical-stage product candidate, OP-233, targets stress urinary incontinence, a condition characterized by involuntary urine loss during physical activities that exert pressure on weakened pelvic floor muscles or urethral sphincters. Through its research and development efforts, Outpost Medicine aims to address significant unmet medical needs in these areas.

Aquinnah Pharmaceuticals, Inc., founded in 2014 and based in Cambridge, Massachusetts, is a pharmaceutical company dedicated to developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on innovative research aimed at modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its specialized approach, Aquinnah Pharmaceuticals aims to address critical unmet medical needs in the field of neurodegeneration.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. The company specializes in developing novel small-molecule antiviral therapeutics through its innovative drug discovery platform, which utilizes cell-free protein synthesizing systems. This platform enables the identification of small molecule drugs that may be overlooked by traditional pharmaceutical screening methods. Prosetta Biosciences is engaged in collaborative efforts with both commercial and non-profit partners to advance compounds targeting a variety of human diseases, including oncology, neurodegenerative disorders, and infectious diseases. The company's focus on modulating the assembly of multi-protein complexes within cells positions it as a significant player in the biopharmaceutical sector.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

ArmaGen, Inc. is a clinical-stage biotechnology company based in San Diego, California, specializing in the development of therapies for severe neurological diseases. The company focuses on lysosomal storage disorders and neurodegenerative diseases, including Hunter syndrome, Hurler syndrome, Sanfilippo A syndrome, and metachromatic leukodystrophy. ArmaGen's innovative product candidates, such as AGT-182 and AGT-181, are designed to penetrate the blood-brain barrier, allowing for more effective treatment of neurological complications associated with these conditions. Founded in 2001, ArmaGen aims to improve the quality of life for patients suffering from these challenging disorders through its targeted therapeutic approaches.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

LigoCyte Pharmaceuticals is a biotechnology company focused on developing innovative vaccines and therapeutic monoclonal antibodies aimed at treating inflammatory and infectious diseases. The company specializes in creating commercial vaccines and biodefense vaccines, with notable products including Norovirus VLP Vaccines, which mimic the live virus's surface configuration without causing infection, and an Influenza VLP Vaccine that offers protection against multiple strains, including A/H1N1 and A/H3N2. Additionally, LigoCyte is involved in the development of an anthrax vaccine and Anti-CD103 monoclonal antibodies, which play a role in the retention of activated lymphocytes at sites of inflammation. By advancing its proprietary products into human clinical testing, LigoCyte is positioned for growth in the biotechnology sector, contributing to the field of immunomodulatory drugs that target disease processes rather than merely alleviating symptoms.

Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing regenerative therapies. Founded in 2007, it focuses on treating life-threatening diseases using non-viral gene therapies that activate natural processes to repair the body.

Intellikine is a biopharmaceutical company focused on the discovery and development of innovative small molecule therapies that target the PI3K/Akt/mTOR signaling pathway. The company specializes in creating drugs designed to treat various conditions, including cancer, inflammation, and autoimmune disorders. Its product portfolio features several notable candidates, such as INK128, an orally-available inhibitor that targets TORC1/2 for solid tumor malignancies, and INK1197, a dual PI3K selective inhibitor aimed at treating immune-mediated inflammatory diseases like rheumatoid arthritis and asthma. Intellikine is dedicated to fostering a skilled team and a robust discovery platform to accelerate the development of kinase inhibitors that have the potential to lead to significant medical advancements.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

IDM Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies aimed at destroying cancer cells and preventing tumor recurrence. The company's products work by activating the immune system or triggering a specific adaptive immune response, thereby enabling effective cancer control while prioritizing patient quality of life. IDM Pharma is committed to addressing the needs of both patients and the physicians who treat them, striving to maximize the therapeutic and commercial potential of its novel treatments.

Millennium Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of cancer treatments. Established in 1993 and headquartered in Cambridge, Massachusetts, the company operates facilities in San Diego, San Francisco, Tsukuba, and Osaka. Millennium is known for developing VELCADE, an injectable therapy used for patients with multiple myeloma and relapsed mantle cell lymphoma. As of 2008, it has functioned as a subsidiary of Takeda Pharmaceutical Company, enhancing its capabilities and reach in the global market for oncology medications.

Takeda Bio Development Center Limited engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. Takeda Bio Development Center Ltd. was formerly known as Amgen Kabushiki Kaisha. As a result of the acquisition of Amgen Kabushiki Kaisha by Takeda Pharmaceutical Co., Amgen Kabushiki Kaisha's name was changed. As of April 1, 2008, Takeda Bio Development Center Ltd. operates as a subsidiary of Takeda Pharmaceutical Co. Ltd.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Xenon Pharmaceuticals is a biopharmaceutical company dedicated to developing novel medicines for neurological disorders. It focuses on rare genetic defects as drug targets, leveraging its proprietary discovery platform called Extreme Genetics. The company's pipeline includes XEN1101 and XEN496 for epilepsy treatment.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to developing first-in-class therapeutics targeting ion channels. Utilising proprietary proteomics technology, Lectus aims to create innovative treatments focused on pain management and urinary bladder disorders.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Syrrx Inc is a biotechnology company that specializes in the development of novel small molecule drugs aimed at treating cancer, metabolic diseases, and inflammation. By leveraging its expertise in high-throughput structural biology, Syrrx is able to determine the three-dimensional structures of drug targets that have been validated in human clinical trials. This foundational work supports their iterative, structure-based drug design programs, which efficiently generate potential drug candidates. The company has established partnerships for the development and commercialization of its designed human dipeptidyl peptidase IV (DPP IV) inhibitors for the treatment of type 2 diabetes and other significant diseases. Additionally, Syrrx has a strategic alliance focused on discovering and early developing inhibitors that target human histone deacetylases (HDACs) and 11β-hydroxysteroid dehydrogenase type 1 (HSD1), further expanding its therapeutic portfolio.

BioNumerik Pharmaceuticals, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs for cancer treatment and supportive care. Founded in 1992 and based in San Antonio, Texas, the company’s product portfolio includes Tavocept, which targets oncology and non-oncology indications, and Karenitecin, a novel anti-tumor drug belonging to the camptothecin class. BioNumerik is also advancing various preclinical oncology research programs, exploring areas such as DNA methyltransferase modulators, novel platinum drugs, small molecule Bcl-2 inhibitors, and new formulations of taxanes. The company's multi-disciplinary approach integrates chemistry, biology, and advanced computing technologies to enhance the understanding of drug mechanisms and interactions.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.